Under a tenth of people who could benefit from GLP-1 drugs like Wegovy can access them, warns the WHO as it issues its first guidance on the medications.
With in excess of 1,000,000,000 people worldwide currently classified as obese, it is advocating for increased and just availability to this class of drugs.
Based on projections, more than two billion will be obese by 2030 unless action is taken.
"The latest guidelines recognises that obesity is a long-term condition that can be treated with comprehensive and ongoing care," stated WHO director-general Tedros Adhanom Ghebreyesus.
Significant expense, insufficient output, and supply-chain constraints are significant barriers to widespread access to the jabs that can aid individuals in losing considerable weight, says the agency.
GLP-1 Therapy Scarcity
Even in the present most favorable scenario, the manufacturing of GLP-1 therapies would only suffice for about 100 million people – less than 10% of eligible patients, as stated by the health organization.
The guideline calls on governments and firms to expand access, via approaches like licensing agreements.
Exclusive production rights on semaglutide – the primary component of the drug Wegovy – is scheduled to end in a number of nations in 2026.
How Weight-Loss Jabs Function
GLP-1 drugs mimick a biological compound to slow digestion, suppress the appetite and increase feelings of fullness so individuals eat less.
People typically start to lose weight within a few weeks of beginning the regular doses.
Studies points to people may see weight return within a year of stopping the treatment, because their usual appetite return.
Being above a healthy weight elevates your risk for experiencing health problems, including type 2 diabetes, cardiovascular issues, stroke, and some malignancies.
Excess weight impacts individuals in all nations and was responsible for 3.7 million fatalities worldwide in 2024, according to the WHO.
